
AstraZeneca’s Calquence shows strength in most common adult leukaemia
pharmafile | June 6, 2019 | News story | Research and Development | AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma
AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met its primary endpoint when used in combination with obinutuzumab.
The data showed that Calquence use led to a “statistically-significant and clinically-meaningful improvement” in progression-free survival (PFS) compared to chemotherapy-based chlorambucil and obinutuzumab combo treatment, meeting its primary endpoint early
The study also met its secondary endpoint, improving PFS by a “statistically-significant and clinically-meaningful” margin compared to compared to a regimen of chemotherapy and obinutuzumab.
While specifics of the data were not revealed, AZ confirmed it would be presenting the full results at an upcoming medical meeting.
“These findings confirm the superiority of Calquence as a monotherapy and also in combination over standard-of-care treatments for chronic lymphocytic leukaemia,” commented José Baselga, AZ’s Executive Vice President, Oncology R&D.
The positive results from both the ELEVATE-TN and ASCEND trials will serve as the foundation for regulatory submissions later this year.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






